企业名片

AusBioTherapeutics Pty Ltd was founded in 2010, focusing on the research and development of innovative stem cell-derived therapies for chronic diseases. With a team of over 150 scientists and researchers, the company has established state-of-the-art laboratories in Sydney and Melbourne, equipped with advanced cell culture facilities and GMP-compliant production lines. Backed by AU$120 million in funding from Australian government grants and private investors, ABT has filed 38 international patents and established strategic partnerships with leading research institutions including the University of Sydney and Walter and Eliza Hall Institute of Medical Research.
The company's core mission is to translate cutting-edge stem cell technology into clinical applications that address unmet medical needs. In 2024, ABT launched its flagship product StemCellPro Therapy, which has shown promising results in treating osteoarthritis and neurodegenerative diseases in Phase II clinical trials. With a strong focus on Asia-Pacific markets, the company is actively seeking regulatory approval in China, Singapore, and South Korea to bring its innovative therapies to patients worldwide.